GlassScriptPhysician profile
Cesar L Dua
NPI 1881676302
$553.53
in general payments reported to CMS, 2019-2025
13 companies · $40.90 in 2025
The $40.90 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $53.10 · 2021: $108 · 2022: $118 · 2023: $88.86 · 2025: $40.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $100.03 | 2019 | |
| Hologic Sales and Service, LLC | $84.83 | 2019-2022 | |
| Sanofi Pasteur INC. | $62.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.01 | 2021-2023 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.76 | 2020-2021 | |
| Pfizer INC. | $37.53 | 2023 | |
| Cranial Technologies, INC | $36.82 | 2022-2025 | Doc Band |
| Novo Nordisk INC | $35.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.59 | 2023 | |
| Scilex Pharmaceuticals INC. | $20.56 | 2022 | |
| Lilly USA, LLC | $20.53 | 2020 | |
| Cipher Pharmaceuticals US LLC | $19.23 | 2025 | Natroba, Spinosad |
| Biohaven Pharmaceutical Holding Company LTD. | $16.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.